Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Naïve B-cell receptors (BCRs) specific for diphtheria toxoid, tetanus toxoid, and pertussis antigens are membrane-bound immunoglobulins expressed on the surface of B-lymphocytes that have not yet encountered these specific pathogens (Janeway's Immunobiology, 2016). These receptors function as the primary sensors for the adaptive immune system, recognizing specific epitopes on the toxoids and bacterial components found in DTaP and Tdap vaccines (CDC, 2022). Upon binding to their cognate antigens, these BCRs initiate intracellular signaling cascades involving kinases like Lyn and Syk, which lead to B-cell activation and proliferation (Nature Reviews Immunology, 2010). This process is essential for the formation of germinal centers where B-cells undergo affinity maturation and class-switch recombination. Ultimately, this interaction results in the generation of long-lived memory B-cells and plasma cells that secrete high-affinity IgG antibodies, providing protective immunity against diphtheria, tetanus, and pertussis (StatPearls, 2023). Therapeutic targeting of these receptors via vaccination is a cornerstone of public health, preventing severe respiratory and neurological complications associated with these bacterial infections (WHO, 2020).
Vaccine antigens bind to specific naïve B-cell receptors, inducing receptor clustering and activation of intracellular signaling pathways involving kinases such as Lyn and Syk (Nature Reviews Immunology, 2010). This triggers B-cell proliferation, germinal center formation, and differentiation into antibody-secreting plasma cells and memory B-cells (Janeway's Immunobiology, 2016).
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Naïve B-cell receptors specific for diphtheria toxoid, tetanus toxoid, and pertussis antigens (BCR).